Result:Weak#Base effect
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 0.08 | 25.5% | 8.7% |
| Total Income | 0.09 | 16.5% | 12.3% |
| Expenditure | 0.08 | 46.9% | 5.0% |
| PBT | 0.01 | 60.5% | 49.1% |
| Net Profit | 0.01 | 60.1% | 49.2% |
| OPM | -5.01% | 15.33pp | 15.10pp |
| NPM | 7.19% | 13.82pp | 5.23pp |
| EPS | 0.01 | 50.0% | 50.0% |
Pharma micro-cap on a negligible revenue base: core revenue grew 8.7% and operating loss narrowed (OPM -5.0% vs -20.1%), but adjusted PAT fell 49.2% YoY as other income collapsed, leaving net margin down and the business still operating-loss-making.
Informational and educational content only. Not investment advice.